Biomarkers play an essential role in the diagnosis and management of patients with gastric and gastroesophageal junction (GEJ) cancers, according to Rutika J. Mehta, MD, MPH, who added that many ongoing trials are working to identify the optimal treatment of subgroups whose tumors harbor different genomic alterations, such as HER2 mutations.
https://www.onclive.com/view/research-efforts-abound-in-her2-positive-gastric-and-gej-cancers